Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/680,935
				Filing Date	October 2, 2003
				First Named Inventor	David Bar-Or
				Art Unit	1644
				Examiner Name	Amy E. Juedes
Sheet	1	of	1	Attorney Docket Number	6134-81

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.[1]	Document Number Number-kind Code [2] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]; Number[4]; Kind Code[5] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)		
Examiner Initials*	Cite No.[1]	
	1	Lim et al. "Characterization of transthyretin variants in familial transthyretin amyloidosis by mass spectrometric peptide mapping and DNA sequence analysis", 2002, Anal. Chem. 74, pages 741-751
	2	Kishikawa, "Enhanced amyloidogenicity of sulfonated transthyretin in vitro, a hypothetical etiology of senile amyloidosis" 1999, Amyloid, Vol. 6, No. 3, pages 183-186
	3	Haque et al. "Cysteinylation of MHC class II ligands: peptide endocytosis and reduction within APC influences T cell recognition.", The Journal of Immunology, 2001, 166(7), 4543-4551
	4	Guo W et al., 2002 "Tyrosine phosphorylation of the NR2B subunit of the NMDA receptor in the spinal cord during the development and maintenance of inflammatory hyperalgesia" J. Neurosci. Jul 15; 22(14):6208-17
	5	Han J et al., "A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells" 1994 Science 265, 808-811

Examiner Signature	/Amy Juedes/	Date Considered	07/19/2010

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AJ/